Literature DB >> 25779621

Estimating unbiased economies of scale of HIV prevention projects: a case study of Avahan.

Aurélia Lépine1, Anna Vassall2, Sudha Chandrashekar3, Elodie Blanc4, Alexis Le Nestour5.   

Abstract

Governments and donors are investing considerable resources on HIV prevention in order to scale up these services rapidly. Given the current economic climate, providers of HIV prevention services increasingly need to demonstrate that these investments offer good 'value for money'. One of the primary routes to achieve efficiency is to take advantage of economies of scale (a reduction in the average cost of a health service as provision scales-up), yet empirical evidence on economies of scale is scarce. Methodologically, the estimation of economies of scale is hampered by several statistical issues preventing causal inference and thus making the estimation of economies of scale complex. In order to estimate unbiased economies of scale when scaling up HIV prevention services, we apply our analysis to one of the few HIV prevention programmes globally delivered at a large scale: the Indian Avahan initiative. We costed the project by collecting data from the 138 Avahan NGOs and the supporting partners in the first four years of its scale-up, between 2004 and 2007. We develop a parsimonious empirical model and apply a system Generalized Method of Moments (GMM) and fixed-effects Instrumental Variable (IV) estimators to estimate unbiased economies of scale. At the programme level, we find that, after controlling for the endogeneity of scale, the scale-up of Avahan has generated high economies of scale. Our findings suggest that average cost reductions per person reached are achievable when scaling-up HIV prevention in low and middle income countries.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Avahan; Causal inference; Cost data; Economies of scale; Efficiency; HIV prevention; India; Scale-up

Mesh:

Year:  2015        PMID: 25779621     DOI: 10.1016/j.socscimed.2015.03.007

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  6 in total

1.  Costs and economies of scale in repeated home-based HIV counselling and testing: Evidence from the ANRS 12249 treatment as prevention trial in South Africa.

Authors:  Marwân-Al-Qays Bousmah; Collins Iwuji; Nonhlanhla Okesola; Joanna Orne-Gliemann; Deenan Pillay; François Dabis; Joseph Larmarange; Sylvie Boyer
Journal:  Soc Sci Med       Date:  2022-05-29       Impact factor: 5.379

2.  The determinants of technical efficiency of a large scale HIV prevention project: application of the DEA double bootstrap using panel data from the Indian Avahan.

Authors:  Aurélia Lépine; Anna Vassall; Sudhashree Chandrashekar
Journal:  Cost Eff Resour Alloc       Date:  2015-03-29

3.  Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale.

Authors:  Lucy Cunnama; Edina Sinanovic; Lebogang Ramma; Nicola Foster; Leigh Berrie; Wendy Stevens; Sebaka Molapo; Puleng Marokane; Kerrigan McCarthy; Gavin Churchyard; Anna Vassall
Journal:  Health Econ       Date:  2016-01-14       Impact factor: 3.046

4.  Large-scale delivery of seasonal malaria chemoprevention to children under 10 in Senegal: an economic analysis.

Authors:  Catherine Pitt; Mouhamed Ndiaye; Lesong Conteh; Ousmane Sy; El Hadj Ba; Badara Cissé; Jules F Gomis; Oumar Gaye; Jean-Louis Ndiaye; Paul J Milligan
Journal:  Health Policy Plan       Date:  2017-11-01       Impact factor: 3.344

5.  HIV prevention costs and their predictors: evidence from the ORPHEA Project in Kenya.

Authors:  Omar Galárraga; Richard G Wamai; Sandra G Sosa-Rubí; Mercy G Mugo; David Contreras-Loya; Sergio Bautista-Arredondo; Helen Nyakundi; Joseph K Wang'ombe
Journal:  Health Policy Plan       Date:  2017-12-01       Impact factor: 3.344

6.  Redefining and revisiting cost estimates of routine ART care in Zambia: an analysis of ten clinics.

Authors:  Austin Tucker; Tannia Tembo; Radhika P Tampi; Jacob Mutale; Mpande Mukumba-Mwenechanya; Anjali Sharma; David W Dowdy; Carolyn B Moore; Elvin Geng; Charles B Holmes; Izukanji Sikazwe; Hojoon Sohn
Journal:  J Int AIDS Soc       Date:  2020-02       Impact factor: 5.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.